<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938742</url>
  </required_header>
  <id_info>
    <org_study_id>13-0032</org_study_id>
    <secondary_id>HHSN272200800005C</secondary_id>
    <nct_id>NCT01938742</nct_id>
  </id_info>
  <brief_title>H7N9 Mix and Match With MF59 in Healthy Adults</brief_title>
  <official_title>A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without MF59 Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This is a Phase II randomized, double-blinded, controlled study in up to 700 males and&#xD;
      non-pregnant females, 19 to 64 years old, inclusive, designed to assess the safety,&#xD;
      reactogenicity, and immunogenicity of a monovalent influenza A/H7N9 virus vaccine&#xD;
      administered at different dosages (3.75, 7.5, or 15 mcg of HA/0.5 mL dose) given with and&#xD;
      without MF59 adjuvant and without adjuvant (15 mcg of HA/0.5 mL dose and 45 mcg of HA/0.75 mL&#xD;
      dose). Subjects will receive two doses via intramuscular injection, approximately 21 days&#xD;
      apart. Safety, reactogenicity, and immunogenicity data will be collected at standard time&#xD;
      points with safety follow-up to continue through one year post dose 2. The duration of the&#xD;
      study for each subject will be approximately 13 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II randomized, double-blinded, controlled study in up to 700 males and&#xD;
      non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all&#xD;
      eligibility criteria. The study is designed to assess the safety, reactogenicity, and&#xD;
      immunogenicity of a monovalent influenza A/H7N9 virus vaccine manufactured by Sanofi Pasteur&#xD;
      administered to healthy adults at different dosages (3.75, 7.5, or 15 mcg of HA/0.5 mL dose)&#xD;
      given with MF59 adjuvant manufactured by Novartis Vaccines and Diagnostics and without&#xD;
      adjuvant (15 mcg of HA/0.5 mL dose and 45 mcg of HA/0.75 mL dose). The A/H7N9 vaccine was&#xD;
      made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Subjects will be&#xD;
      randomly assigned to 1 of 7 groups (up to 100 subjects per group) to receive two doses of the&#xD;
      A/H7N9 vaccine with and without MF59 adjuvant delivered intramuscularly approximately 21 days&#xD;
      apart. The same dosage of A/H7N9 vaccine will be given to subjects at both their first and&#xD;
      second study vaccinations. The primary objectives are to: 1) assess the safety and&#xD;
      reactogenicity of a monovalent influenza A/H7N9 virus vaccine following receipt of two doses&#xD;
      administered with and without MF59 adjuvant; and 2) assess new-onset chronic medical&#xD;
      conditions following receipt of two doses of a monovalent influenza A/H7N9 virus vaccine&#xD;
      administered with and without MF59 adjuvant. The duration of the study for each subject will&#xD;
      be approximately 13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited injection site and systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.</measure>
    <time_frame>Day 0 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of study vaccine-related serious adverse events from the time of the first study vaccination through approximately 13 months after the first study vaccination.</measure>
    <time_frame>Day 0 through Day 386</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater against the A/H7N9 antigen contained in the study vaccine at approximately 21 days after the second study vaccination.</measure>
    <time_frame>Day 42 (21 days post second study vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving seroconversion (pre-vaccination HAI titer &lt;1:10 and post-vaccination HAI titer &gt;/=1:40 or pre-vaccination HAI titer &gt;/=1:10,minimum four-fold rise in post-vaccination HAI antibody titer).</measure>
    <time_frame>Day 42 (21 days post second study vaccination)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of serum HAI and Neut antibody at baseline and at approximately 8 and 21 days after each study vaccination.</measure>
    <time_frame>Day 0, 8, 21, 29, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new-onset chronic medical conditions through 13 months after the first study vaccination</measure>
    <time_frame>Through Day 386 (13 months after the first vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse events from the time of the first study vaccination through approximately 21 days after the last study vaccination.</measure>
    <time_frame>Day 42 (21 days post last study vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater against the A/H7N9 antigen contained in the study vaccine at approximately 8 days after the second study vaccination.</measure>
    <time_frame>Day 29 (8 days after the second study vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater against the A/H7N9 antigen contained in the study vaccine at baseline and at approximately 8 and 21 days after the first study vaccination</measure>
    <time_frame>Day 0, 8 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a serum Neut antibody titer of 1:40 or greater against the A/H7N9 antigen contained in the study vaccine at baseline and at approximately 8 and 21 days after each study vaccination.</measure>
    <time_frame>Day 0, 8, 21, 29, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion (pre-vaccination HAI titer &lt;1:10 and post-vaccination HAI titer &gt;/= 1:40 or pre-vaccination HAI titer &gt;/= 1:10 and minimum four-fold rise post-vaccination HAI antibody titer)</measure>
    <time_frame>Day 29 (8 days after the second study vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion (pre-vaccination HAI titer &lt;1:10 and post-vaccination HAI titer &gt;/=1:40 or pre-vaccination HAI titer &gt;/=1:10 and minimum four-fold rise post-vaccination HAI antibody titer)</measure>
    <time_frame>Day 0, 8 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion (pre-vaccination Neut titer &lt;1:10 and post-vaccination Neut titer &gt;/=1:40 or pre-vaccination Neut titer &gt;/=1:10 and minimum four-fold rise post-vaccination Neut antibody titer).</measure>
    <time_frame>Day 0, 8, 21, 29, and 42</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013</intervention_name>
    <description>Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, &amp; 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF59</intervention_name>
    <description>MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 &amp; 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Provide written informed consent prior to initiation of any study procedures. -Are able to&#xD;
        understand and comply with planned study procedures and be available for all study visits.&#xD;
        -Are males or non-pregnant females, 19 to 64 years old, inclusive. -Are in good health, as&#xD;
        determined by vital signs (oral temperature, pulse, and blood pressure), medical history,&#xD;
        and targeted physical examination based on medical history to ensure any existing medical&#xD;
        diagnoses or conditions (except those in the Subject Exclusion Criteria) are stable.&#xD;
        Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site&#xD;
        principal investigator or appropriate sub-investigator, they pose no additional risk to&#xD;
        subject safety or assessment of reactogenicity and immunogenicity. Note: Topical, nasal,&#xD;
        and inhaled medications (with the exception of steroids as outlined in the Subject&#xD;
        Exclusion Criteria (see section 5.2)), vitamins, and contraceptives are permitted. -Oral&#xD;
        temperature is less than 100.4 degrees F. -Pulse is 50 to 115 bpm, inclusive. -Systolic&#xD;
        blood pressure is 85 to 150 mmHg, inclusive. -Diastolic blood pressure is 55 to 95 mmHg,&#xD;
        inclusive. -Female subjects of childbearing potential who are not surgically sterile via&#xD;
        tubal sterilization, bilateral oophorectomy, or hysterectomy or who are not postmenopausal&#xD;
        for &gt;/= 1 year must agree to practice highly effective contraception that may include, but&#xD;
        is not limited to, abstinence from intercourse with a male partner, monogamous relationship&#xD;
        with a vasectomized partner, male condoms with the use of applied spermicide, intrauterine&#xD;
        devices, and licensed hormonal methods with use of a highly effective method of&#xD;
        contraception for a minimum of 30 days prior to study product exposure and agree to&#xD;
        practice highly effective contraception for the duration of study product exposure,&#xD;
        including 2 months (defined as 60 days)after the last study vaccination. A highly effective&#xD;
        method of contraception is defined as one which results in a low failure rate (i.e., less&#xD;
        than 1 percent per year) when used consistently and correctly. Method of contraception will&#xD;
        be captured on the appropriate data collection form. -Female subjects of childbearing&#xD;
        potential must have a negative urine or serum pregnancy test within 24 hours prior to study&#xD;
        vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Have an acute illness within 72 hours prior to study vaccination. -Have any condition&#xD;
        that, in the opinion of the site principal investigator or appropriate sub-investigator,&#xD;
        would place the subject at an unacceptable risk of injury, render the subject unable to&#xD;
        meet the requirements of the protocol, or confound the interpretation of the results. -Have&#xD;
        an acute or chronic medical condition that, in the opinion of the site principal&#xD;
        investigator or appropriate sub-investigator, would render vaccination unsafe, or would&#xD;
        interfere with the evaluation of responses. -Have immunosuppression as a result of an&#xD;
        underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy&#xD;
        (cytotoxic) within 3 years prior to study vaccination. -Have known active neoplastic&#xD;
        disease or a history of any hematologic malignancy. -Have known HIV, hepatitis B, or&#xD;
        hepatitis C infection. -Have known hypersensitivity or allergy to eggs, egg or chicken&#xD;
        protein, squalene-based adjuvants, or other components of the study vaccine. -Have a&#xD;
        history of severe reactions following previous immunization with licensed or unlicensed&#xD;
        influenza virus vaccines. -Have a history of Guillain-Barr√© Syndrome. - Have a history of&#xD;
        neuralgia, paresthesia, neuritis, convulsions, or encephalomyelitis within 90 days prior to&#xD;
        study vaccination. -Have a history of autoimmune disease, including but not limited to&#xD;
        neuroinflammatory diseases, vasculitis, clotting disorders, dermatitis, arthritis,&#xD;
        thyroiditis, or muscle, liver or kidney disease. -Have a history of alcohol or drug abuse&#xD;
        within 5 years prior to study vaccination. -Have any diagnosis, current or past, of&#xD;
        schizophrenia, bipolar disease, or other psychiatric diagnosis that may interfere with&#xD;
        subject compliance or safety evaluations. -Have been hospitalized for psychiatric illness,&#xD;
        history of suicide attempt, or confinement for danger to self or others within 10 years&#xD;
        prior to study vaccination. -Have taken oral or parenteral corticosteroids of any dose&#xD;
        within 30 days prior to study vaccination. -Have taken high-dose inhaled corticosteroids&#xD;
        within 30 days prior to study vaccination. High-dose defined as &gt;800mcg/day of&#xD;
        beclomethasone dipropionate CFC or equivalent. -Received any licensed live vaccine within&#xD;
        30 days or any licensed inactivated vaccine within 14 days prior to the first study&#xD;
        vaccination or planned receipt of any vaccine from the first study vaccination through the&#xD;
        follow-up visit at approximately 21 days after the last study vaccination. This is&#xD;
        inclusive of licensed seasonal influenza vaccines. -Received immunoglobulin or other blood&#xD;
        products (with exception of Rho D immunoglobulin) within 90 days prior to study&#xD;
        vaccination. -Received an experimental agent (vaccine, drug, biologic, device, blood&#xD;
        product, or medication) within 30 days prior to the first study vaccination, or expects to&#xD;
        receive an experimental agent other than from participation in this study during the&#xD;
        13-month study period. -Are participating or plan to participate in another clinical trial&#xD;
        with an interventional agent (licensed or unlicensed vaccine, drug, biologic, device, blood&#xD;
        product, or medication) during the 13-month study period. -Prior participation in a&#xD;
        clinical trial of influenza A/H7 vaccine and assigned to a group receiving influenza A/H7&#xD;
        vaccine (does not apply to documented placebo recipients) or have a history of A/H7 actual&#xD;
        or potential exposure or infection prior to the first study vaccination. -Plan to travel&#xD;
        outside the U.S. (continental U.S., Hawaii and Alaska) in the time between the first study&#xD;
        vaccination and 42 days after the first study vaccination. -Female subjects who are&#xD;
        breastfe eding or plan to breastfeed at any given time from the first study vaccination&#xD;
        until 30 days after their last study vaccination. -Blood donation within 30 days prior to&#xD;
        enrollment and within 30 days after the last blood draw (only for a subset of healthy adult&#xD;
        subjects - up to 75 volunteers, 19-64 years old, enrolled at the Emory VTEU site, who&#xD;
        consent to blood donation for the immunology exploratory assays).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Vaccine Center - The Hope Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030-1705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa - Infectious Disease Clinic</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-5302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR; DMID 13-0032 H7N9 Vaccine Study Group. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA. 2014 Oct 8;312(14):1409-19. doi: 10.1001/jama.2014.12854.</citation>
    <PMID>25291577</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <disposition_first_submitted>March 26, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2015</disposition_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>A/H7N9,Adjuvant,Immunogenicity,Influenza,MF59,Monovalent,Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

